Aliases & Classifications for Ocular Hyperemia

MalaCards integrated aliases for Ocular Hyperemia:

Name: Ocular Hyperemia 12 15 74
Hyperemia of Conjunctiva 12
Hyperemia Eye 12

Classifications:



External Ids:

Disease Ontology 12 DOID:1248
SNOMED-CT 69 76849009
UMLS 74 C0155169

Summaries for Ocular Hyperemia

MalaCards based summary : Ocular Hyperemia, also known as hyperemia of conjunctiva, is related to adenoid hypertrophy and red-green color blindness, and has symptoms including redness of eye An important gene associated with Ocular Hyperemia is EHMT2 (Euchromatic Histone Lysine Methyltransferase 2), and among its related pathways/superpathways are Pathways in cancer and Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs). The drugs Bimatoprost and Latanoprost have been mentioned in the context of this disorder. Affiliated tissues include eye, thyroid and testes, and related phenotypes are homeostasis/metabolism and behavior/neurological

Related Diseases for Ocular Hyperemia

Graphical network of the top 20 diseases related to Ocular Hyperemia:



Diseases related to Ocular Hyperemia

Symptoms & Phenotypes for Ocular Hyperemia

UMLS symptoms related to Ocular Hyperemia:


redness of eye

MGI Mouse Phenotypes related to Ocular Hyperemia:

47
# Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 10.14 ALK BCL2L11 CD40 IFNB1 IGF2 IGFBP3
2 behavior/neurological MP:0005386 10.13 ALK EHMT2 IGF2 IGFBP3 PTGER3 RPE65
3 immune system MP:0005387 10.11 BCL2L11 CD40 EFS EHMT2 IFNB1 IGF2
4 hematopoietic system MP:0005397 10.09 BCL2L11 CD40 EFS EHMT2 IFNB1 IGF2
5 endocrine/exocrine gland MP:0005379 10 ALK BCL2L11 CD40 EHMT2 IGF2 IGFBP3
6 integument MP:0010771 9.92 ALK BCL2L11 IGF2 IGFBP3 PTGER3 SLC6A2
7 nervous system MP:0003631 9.85 ALK BCL2L11 CD40 EHMT2 IFNB1 IGF2
8 neoplasm MP:0002006 9.65 ALK BCL2L11 IFNB1 SOD1 TRPV1
9 pigmentation MP:0001186 9.26 ALK BCL2L11 IGFBP3 RPE65
10 renal/urinary system MP:0005367 9.1 BCL2L11 CD40 EFS IGF2 PTGER3 TRPV1

Drugs & Therapeutics for Ocular Hyperemia

Drugs for Ocular Hyperemia (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 268)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Bimatoprost Approved, Investigational Phase 4,Phase 3,Phase 2 155206-00-1 5311027
2
Latanoprost Approved, Investigational Phase 4,Phase 3,Phase 2 130209-82-4 5311221 5282380
3
Tacrolimus Approved, Investigational Phase 4 104987-11-3 445643 439492 6473866
4
Travoprost Approved Phase 4,Phase 3 157283-68-6 5282226
5
Methylprednisolone hemisuccinate Approved Phase 4,Phase 3,Phase 2,Phase 1 2921-57-5
6
Prednisolone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 50-24-8 5755
7
Prednisolone phosphate Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 302-25-0
8
Methylprednisolone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 83-43-2 6741
9
Ganciclovir Approved, Investigational Phase 4,Phase 3 82410-32-0 3454
10
Loteprednol Approved, Experimental Phase 4,Phase 3,Phase 2,Not Applicable 82034-46-6, 129260-79-3 444025 9865442
11
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Not Applicable 1177-87-3
12
Dexamethasone Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Not Applicable 50-02-2 5743
13
Moxifloxacin Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 354812-41-2, 151096-09-2 152946
14
Ethinyl Estradiol Approved Phase 4,Phase 3,Phase 2,Not Applicable 57-63-6 5991
15
Estradiol Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Not Applicable 50-28-2 5757
16
Polyestradiol phosphate Approved Phase 4,Phase 3,Phase 2,Not Applicable 28014-46-2
17
Norgestimate Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 35189-28-7 6540478
18
Timolol Approved Phase 4,Phase 3 26839-75-8 33624 5478
19
Epinastine Approved, Investigational Phase 4 80012-43-7 3241
20
Histamine Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 51-45-6 774
21
Temazepam Approved, Investigational Phase 4 846-50-4 5391
22
Methimazole Approved Phase 4 60-56-0 1349907
23
Propranolol Approved, Investigational Phase 4 525-66-6 4946
24
Metoprolol Approved, Investigational Phase 4 37350-58-6, 51384-51-1 4171
25
Diclofenac Approved, Vet_approved Phase 4 15307-86-5 3033
26
Bepotastine Approved Phase 4,Phase 3,Phase 2 125602-71-3, 190786-44-8 2350
27
Miconazole Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Not Applicable 22916-47-8 4189
28
Dipivefrin Approved Phase 4,Phase 2,Phase 1 52365-63-6 3105
29
Tobramycin Approved, Investigational Phase 4,Phase 3,Not Applicable 32986-56-4 5496 36294
30
Alcaftadine Approved Phase 4,Phase 3 147084-10-4 19371515
31
Hyaluronic acid Approved, Vet_approved Phase 4,Phase 2,Phase 1 9004-61-9 53477741
32
Glycerol Approved, Investigational Phase 4 56-81-5 753
33
Acetazolamide Approved, Vet_approved Phase 4 59-66-5 1986
34
Dorzolamide Approved Phase 4,Phase 3 120279-96-1 3154 5284549
35
Dinoprost tromethamine Approved, Vet_approved Phase 4 38562-01-5 5282415
36
Dinoprost Approved, Investigational Phase 4 551-11-1 5283078
37
Modafinil Approved, Investigational Phase 4,Phase 3,Phase 1 68693-11-8 4236
38
Prednisolone hemisuccinate Experimental Phase 4,Phase 3,Phase 2,Phase 1 2920-86-7
39
SB-649868 Experimental, Investigational Phase 4 110-16-7, 110-17-8 444972
40
Bromfenac Approved July 1997 Phase 4,Phase 3,Phase 2 91714-94-2 60726
41 Pharmaceutical Solutions Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
42 Ophthalmic Solutions Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
43 Antihypertensive Agents Phase 4,Phase 3,Phase 2
44 Immunologic Factors Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
45 Immunosuppressive Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
46 Calcineurin Inhibitors Phase 4,Phase 3,Phase 2,Not Applicable
47 Anti-Infective Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
48 Anti-Inflammatory Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
49 Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
50 Protective Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable

Interventional clinical trials:

(show top 50) (show all 245)
# Name Status NCT ID Phase Drugs
1 Safety and Efficacy Assessment of Monoprost® in Comparison With Lumigan® 0.01 % and Lumigan® 0.03% Unit Dose Unknown status NCT02017327 Phase 4 Monoprost;Lumigan 0.01%;Lumigan 0.03% Unit Dose
2 Topical Tacrolimus in Vernal Keratoconjunctivitis Unknown status NCT02456025 Phase 4 Topical tacrolimus
3 Generic Travoprost Versus Brand Name Travoprost in Patients With Primary Open Angle Glaucoma or Ocular Hypertension Unknown status NCT02796560 Phase 4 Brand name travoprost;Generic travoprost
4 A Safety and Efficacy Study of Bimatoprost 0.01% in Primary Open-Angle Glaucoma (POAG) or Ocular Hypertension (OH) Completed NCT01594970 Phase 4 Bimatoprost 0.01%
5 A Study of LUMIGAN® RC in the Clinical Setting Completed NCT01833741 Phase 4 Bimatoprost 0.01%
6 Efficacy of Changing to DUOTRAV® From Prior Therapy Completed NCT01327599 Phase 4 Travoprost 0.004%+Timolol 0.5% ophthalmic solution
7 An Efficacy and Tolerability Study of TRAVATAN® Versus LUMIGAN® Completed NCT01664039 Phase 4 Travoprost 0.004% ophthalmic solution;Bimatoprost 0.01% ophthalmic solution
8 Effect of NSAID on Travoprost-induced Conjunctival Hyperemia and IOP Reduction in Normal Eyes Completed NCT02136589 Phase 4 dicrofenac and travoprost
9 Ocular Surface Tolerability Study of Prostaglandin Analogues in Patients With Open-Angle Glaucoma or Ocular Hypertension Completed NCT01253902 Phase 4 bimatoprost ophthalmic solution 0.01%;travoprost ophthalmic solution 0.004%;latanoprost ophthalmic solution 0.005%
10 Evaluation of the Efficacy of Topical Ophthalmic Steroids in a Modified Conjunctival Allergen Challenge (CAC) Model Completed NCT01534195 Phase 4 Prednisolone Sodium Phosphate Ophthalmic Solution 1%;Tears Naturale II Ophthalmic Solution
11 Evaluation of Hyperemia With the Use of Ocular Prostaglandin Analogues Completed NCT00539526 Phase 4 Bimatoprost 0.03%;travoprost 0.004%;latanoprost 0.005% eye drops
12 Bimatoprost 0.03% Versus Travoprost 0.004% in Patients Currently on Latanoprost 0.005% Completed NCT00440011 Phase 4 bimatoprost 0.03% eye drops;travoprost 0.004% eye drops
13 Effectiveness of Olopatadine HCl Ophthalmic Solution for the Treatment of Allergic Conjunctivitis in Japan Completed NCT02251613 Phase 4 Olopatadine HCl ophthalmic solution, 0.1%;Epinastine HCl ophthalmic solution, 0.05%
14 A Study of Bimatoprost in the Treatment of Primary Open Angle Glaucoma and Ocular Hypertension Completed NCT02061683 Phase 4 Bimatoprost 0.03%
15 Long-Term Safety of Bimatoprost Ophthalmic Solution in Patients With Glaucoma or Ocular Hypertension Completed NCT01298700 Phase 4 bimatoprost 0.01% ophthalmic solution;bimatoprost 0.03% ophthalmic solution
16 A Study to Compare Ocular Safety and Tolerability of Prednisolone Acetate 0.5% Eye Drops Versus Vehicle in Healthy Volunteers Completed NCT00134992 Phase 4 Prednisolone acetate
17 20- Versus 23- Gauge System for Pars Plana Vitrectomy Completed NCT00411970 Phase 4
18 Adjuvant Treatment of Graves´ Ophthalmopathy With NSAID (aGO Study) Completed NCT01458600 Phase 4 Diclofenac;Methimazole;L-thyroxin;Propranolol;Metoprolol
19 Evaluation of Prednisolone in a Modified Conjunctival Allergen Challenge Model Completed NCT01730872 Phase 4 Prednisolone Sodium Phosphate Ophthalmic Solution 1%;Tears Naturale II Ophthalmic Solution
20 A Placebo Controlled Comparison of Topical Zirgan Versus Genteal Gel for the Treatment of Adenovirus Conjunctivitis Completed NCT01533480 Phase 4 Zirgan;genteal gel
21 Bepreve vs. Alrex in Subjects With Moderate to Severe Allergic Conjunctivitis Completed NCT01443442 Phase 4 bepotastine besilate, 1.5%;Loteprednol etabonate
22 Efficacy of 0.05 % Cyclosporine Ophthalmic Emulsion Compare With Tear in Meibomian Gland Dysfunction Completed NCT00705510 Phase 4 0.05% cyclosporin eye drop
23 The Effect of Ocular Lubricant Eyedrops on Lid Parallel Conjunctival Folds and Other Signs and Symptoms of Dry Eye Completed NCT01268735 Phase 4 Lubricating eyedrops containing hydroxypropyl-guar
24 A Novel Combined Therapy for Refractory Vernal Keratoconjunctivitis Completed NCT03464435 Phase 4 Tacrolimus
25 Efficacy and Tolerability of an Innovative Formulation of BAK-free Latanoprost Completed NCT03331770 Phase 4 Latanoprost Ophthalmic Product
26 Clinical Evaluation of HPT Treated Rigid Contact Lenses Made From Roflufocon D Completed NCT02553681 Phase 4
27 How Similar Are Changes to the Surface of the Eye When Two Different Glaucoma Eye Drops Are Used? Completed NCT00798694 Phase 4 Xalatan;Travatan Z
28 Clinical Performance of Stenfilcon A Versus Filcon II 3 Completed NCT01808209 Phase 4
29 Investigation of Maintaining Visual Performance Achieved With Cyclosporine Therapy Completed NCT02121847 Phase 4 cyclosporine 0.05% ophthalmic emulsion;carboxymethylcellulose-based lubricant eye drops
30 A Study to Evaluate the Duration of LASTACAFT® in Acute Allergic Conjunctivitis Completed NCT01470118 Phase 4 alcaftadine 0.25% ophthalmic solution;olopatadine 0.2% ophthalmic solution;dextran 70 0.1%/hydroxypropyl methylcellulose 0.3%
31 Pediatric Zylet Safety and Efficacy Study Completed NCT00420628 Phase 4 loteprednol etabonate/tobramycin opthalmic suspension;vehicle
32 Performance and Acceptance of Optive Versus Hylocomod Eyedrops in Patients With Dry Eye Symptoms Completed NCT00761202 Phase 4 A sterile solution containing sodium carboxymethylcellulose and glycerin, preserved with PURITE®;Sodium hyaluronate
33 A Study to Evaluate the Efficacy of Lastacaft® Compared to Pataday™ and Placebo in Patients With Acute Allergic Conjunctivitis Completed NCT01732757 Phase 4 Alcaftadine 0.25%;Olopatadine 0.2%;dextran 70 0.1%/hydroxypropyl methylcellulose 0.3%
34 A Safety and Efficacy Study of OPTIVE FUSION™ With VISMED® Multi for the Management of Dry Eye Completed NCT02117687 Phase 4 carboxymethylcellulose 0.5%/glycerin 0.9%;sodium hyaluronate 0.18%
35 A Study to Compare Ocular Safety and Tolerability of Eye Drops Containing Prednisolone Acetate in Patients With Intraocular Inflammation After Cataract Surgery Completed NCT00170729 Phase 4 Prednisolone acetate
36 COSOPT-S® Treatment Versus Acetazolamide Before Trabeculectomy Completed NCT01228149 Phase 4 Trabeculectomy with preoperative Diamox/DexaEDO treatment;Trabeculectomy with preoperative Cosopt S treatment
37 Daily Disposable Comparison Study Completed NCT02094677 Phase 4
38 Patient Satisfaction With Timolol in Subjects With Open-Angle Glaucoma or Ocular Hypertension Completed NCT00804648 Phase 4 Timolol Maleate in Sorbate;Timolol hemihydrate;Timolol maleate gel forming solution
39 Study of the Progression of Bacterial Conjunctivitis Symptoms Upon Antibiotic Treatment Completed NCT00798577 Phase 4 Vigamox Ophthalmic Solution;BSS placebo
40 Prostaglandin F2-alpha Eye Drops in Thyroid Eye Disease (Bima Study) Completed NCT02059655 Phase 4 Bimatoprost;Eye drop solution
41 A Comparison of Xalatan (Latanoprost) to Apo-latanoprost and Co-latanoprost in the Treatment of Glaucoma Recruiting NCT02792803 Phase 4 Xalatan;Apo-Latanoprost;Co-Latanoprost
42 Efficacy and Safety of PRO-155 on Inflammation of the Conjunctival Surface in Subjects With Grade I-III Pterygium vs Placebo. Recruiting NCT03521791 Phase 4 PRO-155
43 Latanoprost Preserved Versus Unpreserved: Effect on Tear Film Thickness as Measured With OCT Recruiting NCT02585375 Phase 4 Preservative-free latanoprost 50µg/ml;Preserved latanoprost 0.005%
44 Influence of Three Different Formulations of Lachrymal Substitutes on Tear Film Thickness and Other Signs and Symptoms in Patients With Moderate to Severe Dry Eye Syndrome Recruiting NCT02986750 Phase 4
45 Manuka Eye Droops for Treatment of Allergy Not yet recruiting NCT03862053 Phase 4 Manuka honey
46 Efficacy of Changing to DuoTrav® (Travoprost 0.004%/Timolol 0.5% BAK-Free Fixed Combination) From Prior Therapy Terminated NCT01514721 Phase 4 Travoprost/Timolol Maleate BAK-Free Fixed Combination
47 Efficacy of the Brand-name Latanoprost and One of Its Generic Version in Primary Open Angle Glaucoma and Ocular Hypertension Terminated NCT02047630 Phase 4 Generic latanoprost;Brand-name latanoprost
48 Repository Corticotropin Injection in Keratoconjunctivitis Sicca Withdrawn NCT03398018 Phase 4 repository corticotropin injection
49 Phase II/III Study of the Efficacy and Safety of MacuCLEAR MC-1101 in Treating DryAge-Related Macular Degeneration Unknown status NCT02127463 Phase 2, Phase 3 MC-1101;MC-1101 Vehicle
50 Clinical Efficacy of the Drug Ster® Compared With Predfort® in Control of Postoperative Inflammation in Cataract Surgery Unknown status NCT01227876 Phase 3 Ster;Pred Fort

Search NIH Clinical Center for Ocular Hyperemia

Genetic Tests for Ocular Hyperemia

Anatomical Context for Ocular Hyperemia

MalaCards organs/tissues related to Ocular Hyperemia:

42
Eye, Thyroid, Testes, Skin, Endothelial

Publications for Ocular Hyperemia

Articles related to Ocular Hyperemia:

# Title Authors Year
1
A Highly Selective Rho-Kinase Inhibitor (ITRI-E-212) Potentially Treats Glaucoma Upon Topical Administration With Low Incidence of Ocular Hyperemia. ( 30735565 )
2019
2
Seeing red: guiding the management of ocular hyperemia. ( 18528197 )
2008
3
External ocular hyperemia: a quantifiable indicator of spacecraft air quality. ( 8725467 )
1996
4
Automatic quantitative measurement of ocular hyperemia. ( 8974839 )
1995
5
Role of nitric oxide in PGF2 alpha-induced ocular hyperemia. ( 7532135 )
1994
6
Degeneration release of norepinephrine causes transient ocular hyperemia mediated by prostaglandins. ( 4692259 )
1973

Variations for Ocular Hyperemia

Expression for Ocular Hyperemia

Search GEO for disease gene expression data for Ocular Hyperemia.

Pathways for Ocular Hyperemia

Pathways related to Ocular Hyperemia according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1 11.98 ALK BCL2L11 IGF2 PTGER3
2 9.95 IGF2 IGFBP3

GO Terms for Ocular Hyperemia

Biological processes related to Ocular Hyperemia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 positive regulation of apoptotic process GO:0043065 9.56 BCL2L11 IGFBP3 SOD1 TRPV1
2 B cell proliferation GO:0042100 9.43 CD40 IFNB1
3 positive regulation of protein phosphorylation GO:0001934 9.4 CD40 IGF2
4 response to pain GO:0048265 9.37 SLC6A2 TRPV1
5 cellular response to ATP GO:0071318 9.32 SOD1 TRPV1
6 myeloid cell homeostasis GO:0002262 9.16 BCL2L11 SOD1
7 regulation of organ growth GO:0046620 8.96 BCL2L11 SOD1
8 response to nutrient levels GO:0031667 8.8 CD40 EHMT2 SOD1

Sources for Ocular Hyperemia

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
20 FMA
29 GO
30 GTR
31 HGMD
32 HMDB
33 HPO
34 ICD10
35 ICD10 via Orphanet
36 ICD9CM
37 IUPHAR
38 KEGG
39 LifeMap
41 LOVD
43 MedGen
45 MeSH
46 MESH via Orphanet
47 MGI
50 NCI
51 NCIt
52 NDF-RT
55 NINDS
56 Novoseek
58 OMIM
59 OMIM via Orphanet
63 PubMed
65 QIAGEN
70 SNOMED-CT via HPO
71 SNOMED-CT via Orphanet
72 TGDB
73 Tocris
74 UMLS
75 UMLS via Orphanet
Content
Loading form....